

Clinical Edit Criteria Proposal

Drug/Drug Class: Emend® Capsules Clinical Edit

Date: March 21, 2007

Prepared for:

Prepared by: Missouri Medicaid

☐ New Criteria

☒ Revision of Existing Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Emend® (aprepitant oral capsules).

Why was this Issue Selected:

Emend® is a branded drug product containing aprepitant indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. This product is designed to be used in combination with other antiemetic agents prior to chemo or surgery. Emend® has recently received FDA approval for the prevention of postoperative nausea and vomiting. Emend® has not been studied for the treatment of established nausea and vomiting. Emend® is available in 400mg, 80mg and 125mg capsules, as well as a unit-of-use tri-fold pack.

Program-specific information:	Drug	Cost (WAC)
	<ul style="list-style-type: none"> Emend 40mg Emend 80mg Emend 125mg Emend Tri-Fold Pack 	<ul style="list-style-type: none"> \$39.87/cap \$85.10/cap \$107.69/cap \$93.73/cap

Setting & Population: All Patients

Type of Criteria:

☐ Increased risk of ADE

☒ Appropriate Indications

☐ Non-Preferred Agent

☐

Data Sources: ☐ Only administrative databases

☒ Databases + Prescriber-supplied

Setting & Population

- Drug for review: Emend® (aprepitant capsules)
- Age range: All Patients
- Gender: Male and female

Approval Criteria

Approval Diagnoses				
Condition	Submitted ICD-9 Diagnoses	Inferred Drugs	Date Range	Client Approval (Initials)
Cancer	140 - 208	NA	2 years	
	NA	Antineoplastics	12 months	
<i>Elective surgery</i> **	--	--	--	

** Diagnoses subject to clinical review

- Appropriate diagnosis :
 - o Cancer
 - o *Elective surgery*
- Maximum quantity 3 doses per chemotherapy course
- ***Maximum quantity 1 dose within 3 hours prior to inductions of anesthesia***

Denial Criteria

- Lack of appropriate diagnosis
- Quantity exceeds dose limitations

References

1. Facts and Comparisons, p.873c. 2006.
2. USPDI, Micromedex, 2006.
3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2006.
4. Merck & Co., "Emend Product Submission", North Wales, PA 19454; January 2006.

